0
Lung Cancer |

Comparing Noninvasive, Minimally Invasive, and Invasive Strategies in the Initial Mediastinal Staging of Non-small Cell Lung Cancer: A Cost-Effective Analysis

Alex Balekian, MD; Michael Gould, MD
Author and Funding Information

University of Southern California, Los Angeles, CA


Chest. 2013;144(4_MeetingAbstracts):655A. doi:10.1378/chest.1704874
Text Size: A A A
Published online

Abstract

SESSION TITLE: Lung Cancer Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: In non-small cell lung cancer (NSCLC), the mediastinum can be staged with positron emission tomography (PET) scanning, fine needle aspiration (FNA) via endobronchial ultrasound (EBUS) or endoscopic ultrasound (EUS), and surgical mediastinoscopy. We performed a cost-effectiveness analysis to determine the best initial staging step for a peripheral nodule proven to be NSCLC.

METHODS: Using TreeAge 8.0, we constructed a cost-effectiveness model from a payer standpoint. We populated the model using data from the published literature and Medicare through March 2013. We compared four mediastinal staging strategies: EBUS-EUS-FNA without surgical confirmation, EBUS-EUS-FNA with surgical confirmation, PET scan, and mediastinoscopy with EUS-FNA.

RESULTS: We assumed a 30% risk of mediastinal metastasis and sensitivities of 80% for EBUS-EUS-FNA, 86% for mediastinoscopy with EUS-FNA, and 90% for PET. The most cost-effective strategy was EBUS-EUS-FNA without surgical confirmation, followed by mediastinoscopy with EUS-FNA (incremental cost-effectiveness ratio [ICER] of $9,900 per life-year gained) and PET scan (ICER $64,264 per life-year gained). EBUS-EUS-FNA with surgical confirmation of a negative result was the least favorable strategy. The model was most sensitive to the prevalence of N2 disease in the cohort, as well as to the assumption that insurance reimbursement would occur to a single thoracic surgeon combining sequential procedures in a single encounter; however, a sensitivity analysis using a Monte Carlo simulation consistently favored invasive staging strategies. The mediastinoscopy with EUS-FNA staging strategy was consistently the most cost-effective with a willingness-to-pay threshold of only $20,000 to gain one life-year and 15% fewer unnecessary thoracotomies than EBUS-EUS-FNA without surgical confirmation of a negative result.

CONCLUSIONS: Invasive strategies are more cost-effective than non-invasive strategies in the initial step of medastinal staging of NSCLC. Although minimally-invasive strategies appear slightly more cost effective, a low threshold exists to adopt routine mediastinoscopy with EUS-FNA as the preferred staging strategy.

CLINICAL IMPLICATIONS: Non-invasive or minimally-invasive staging strategies, though attractive for patient convenience, increase costs without clearly gaining benefit. A single thoracic surgeon performing these procedures sequentially in a single encounter can expedite care and decrease costs.

DISCLOSURE: The following authors have nothing to disclose: Alex Balekian, Michael Gould

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543